Pharm-Olam Belgium

Pharm-Olam has conducted clinical trials in Belgium since 2001 and we have an office in Testelt (between Antwerp and Brussels). Belgium has the fastest regulatory/ethics process of any EU nation. Our Belgium office also supports regional staff in France and covers the Netherlands. Data from our studies in France and Belgium have supported US NDA and EMA approval in gram positive infections and hepatitis B.

Pharm-Olam is a member of BeCRO, the Belgian Association of CROs.

Agrément CIR tax credits available for French companies conducting studies in France.

Pharm-Olam offers comprehensive services and functional outsourcing for Phase I to IV clinical research studies in Belgium, France, and the Netherlands, including monitoring, regulatory, pharmacovigilance (including EudraVigilance), data management, project management, and biostatistics.

For more information on conducting clinical trials with Pharm-Olam in Belgium, please Contact Us.

Office Location: Testelt (near Antwerp/Brussels)

Belgium Demographics

Population: 10.4 million (97% urbanized)
Median Age: 41.7 years
Language: Dutch, French, and German

Regulatory Authorities

FAMHP (in English)

Clinical Trials in Belgium

clinicaltrials.gov Active Studies
EU Clinical Trials Register Active Studies

Argentina (Buenos Aires), Belarus (Minsk), Belgium (Brussels), Brazil (São Paulo), Bulgaria (Sofia), Canada (Toronto), Croatia (Zagreb), Czech Rep. (Prague), Georgia (Tbilisi), Germany (Munich), Hungary (Budapest), India (Bangalore), Italy (Milan), Kazakhstan (Almaty), Mexico (Mexico City), Poland (Warsaw), Romania (Bucharest), Russia (Moscow, St. Petersburg, Novosibirsk), Serbia (Belgrade), Spain (Madrid), South Africa (Johannesburg), Ukraine (Kiev), United Kingdom (London), United States (Houston, Princeton, Research Triangle Park)